Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-88545223 · 1 trial · 1 indication
The ACR 50 responders are participants with an improvement of greater than or equal to (\>=) 50 percent (%) from baseline in both the tender and swollen joint count and in at least 3 of the 5 assessments (patient's assessment of pain visual analog scale \[VAS\], patient's global assessment of disease activity \[arthritis, VAS\] scale, Physician's global assessment of disease activity VAS scale, Health Assessment Questionnaire and C-reactive protein).
| Arm | Type | Description |
|---|---|---|
| Arm 1: Placebo | PLACEBO_COMPARATOR | Participants will receive matching placebo to JNJ-88545223, from Week 0 to Week 16. |
| Arm 2: JNJ-88545223 Dose 1 | EXPERIMENTAL | Participants will receive JNJ-88545223 Dose 1 from Week 0 to Week 16. |
| Arm 3: JNJ-88545223 Dose 2 | EXPERIMENTAL | Participants will receive JNJ-88545223 Dose 2 from Week 0 to Week 16. |
| Arm 4: JNJ-88545223 Dose 3 | EXPERIMENTAL | Participants will receive JNJ-88545223 Dose 3 from Week 0 to Week 16. |
| Name | Type | Description |
|---|---|---|
| JNJ-88545223 | DRUG | JNJ-88545223 will be administered. |
| Placebo | DRUG | Placebo will be administered. |
Inclusion Criteria: * Have a diagnosis of psoriatic arthritis (PsA) for at least 3 months before the first administration of study intervention and meet classification criteria for Psoriatic Arthritis (CASPAR) at screening * Have active PsA as defined by: (a) At least 3 swollen joints and at least ...
JNJ-88545223 is an investigational small molecule being developed for the treatment of active psoriatic arthritis. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
JNJ-88545223 is being developed by Johnson & Johnson, a company listed on the stock exchange under the ticker symbol JNJ. The drug is in Phase 2 clinical trials for psoriatic arthritis.
JNJ-88545223 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. A Phase 2 trial is currently recruiting participants.
JNJ-88545223 is being studied in a Phase 2 clinical trial registered as NCT07321873. This randomized, double-blind, placebo-controlled study evaluates the efficacy and safety of the drug in participants with active psoriatic arthritis, with an enrollment of 240 participants.
No alternative names for JNJ-88545223 have been disclosed. The drug is identified solely by its development code JNJ-88545223 in clinical trial registrations and company communications.